Processa Pharmaceuticals reports promising Phase 2 results for NGC-Cap

Written by Emily J. Thompson, Senior Investment Analyst

Updated: 17 Dec 25

Processa Pharmaceuticals Inc. experienced a significant price increase of 157.90%, reaching a 20-day high. This surge is attributed to the company's announcement of enhanced efficacy results for the NGC-Cap therapy in a Phase 2 breast cancer study, suggesting a potential breakthrough in treatment options.

The preliminary data indicate that the combination treatment of PCS6422 and capecitabine (NGC-Cap) significantly increases exposure to cancer-killing metabolites while maintaining comparable side effect severity to monotherapy. This promising outcome positions NGC-Cap as a key value driver for Processa, aligning with the company's strategic goal of improving cancer treatment outcomes. The formal interim analysis of 20 patients is anticipated to be completed by early 2026, further validating the efficacy and safety of NGC-Cap.

The implications of these results are substantial, as they not only enhance the company's credibility in the oncology space but also potentially open doors for future clinical applications and partnerships. Investors are likely to respond positively to these developments, reflecting confidence in Processa's innovative approach to cancer treatment.

PCSA

$3.14+Infinity%1D

Analyst Views on PCSA

About PCSA

Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of Next Generation Cancer therapy (NGC) small molecules. The three NGC treatments in its pipeline are NGC-Capecitabine (NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem) and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri) and two non-oncology drug assets are PCS12852, and PCS499. NGC-Cap is a combination of PCS6422 and capecitabine, capecitabine being the oral prodrug of the cancer drug 5-fluorouracil.PCS3117 is an oral analog of gemcitabine that is converted to its active metabolite by a different enzyme system than gemcitabine. PCS11T is a prodrug of the active metabolite of irinotecan (SN-38). PCS12852 is a specific and potent 5HT4 agonist that is in Phase IIB and is a potential treatment for diabetic gastroparesis patients. PCS499 is a drug that can be used to treat unmet medical needs and conditions caused by multiple pathophysiological changes.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Processa Pharmaceuticals reports promising Phase 2 results for NGC-Cap

Analyst Views on PCSA

About PCSA

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

Five Point Holdings Reports Record Q4 2025 Earnings

LPL Financial Reports Strong Q4 2025 Earnings and Growth

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch